...
首页> 外文期刊>Annals of surgical oncology >Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.
【24h】

Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.

机译:直肠癌新辅助治疗后的病理完全缓解可减少远处复发并可以根除局部复发。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The aim of this study was to evaluate the clinical implications of pathologic complete response (pCR) (i.e., T0N0M0) after neoadjuvant chemoradiation and radical surgery in patients with locally advanced rectal cancer. MATERIALS AND METHODS: A single-center, prospectively maintained colorectal cancer database was queried for patients with primary cII and cIII rectal cancer staged by CT and ERUS/MRI undergoing long-course neoadjuvant chemoradiation followed by proctectomy with curative intent between 1997 and 2007. Patients were stratified into pCR and no-pCR groups and compared with respect to demographics, tumor and treatment characteristics, and oncologic outcomes. Outcomes evaluated were 5-year overall survival, disease-free survival, disease-specific mortality, local recurrence, and distant recurrence. RESULTS: The query returned 238 patients (73% male), with a median age of 57 years and median follow-up of 54 months. Of these, 58 patients achieved pCR. Patients with pCR vs no-pCR were statistically comparable with respect to demographics, chemoradiation regimens, tumor distance from anal verge, clinical stage, surgical procedures performed, and follow-up time. No patient with pCR had local recurrence. Overall survival and distant recurrence were also significantly improved for patients achieving pCR. CONCLUSIONS: Achievement of pCR after neoadjuvant chemoradiation is associated with greatly improved cancer outcomes in locally advanced rectal cancer. Future studies should evaluate the relationship between increases in pCR rates and improvements in cancer outcomes in this population.
机译:背景:这项研究的目的是评估局部晚期直肠癌患者新辅助化学放疗和根治性手术后病理完全反应(pCR)(即T0N0M0)的临床意义。材料和方法:查询一个单中心,前瞻性维护的结直肠癌数据库,以查找由CT和ERUS / MRI进行的原发性cII和cIII直肠癌患者,这些患者在1997年至2007年间接受了新疗程的长程新辅助放化疗,然后进行了直肠切除术。将患者分为pCR组和无pCR组,并比较人口统计学,肿瘤和治疗特征以及肿瘤学结局。评估的结果是5年总生存期,无病生存期,疾病特异性死亡率,局部复发和远处复发。结果:该查询返回238名患者(73%的男性),中位年龄为57岁,中位随访时间为54个月。其中58例患者达到了pCR。在人口统计学,化学放疗方案,距肛门边缘的肿瘤距离,临床分期,手术方式和随访时间方面,pCR与无pCR的患者在统计学上具有可比性。没有pCR患者出现局部复发。获得pCR的患者的总生存期和远处复发也得到了显着改善。结论:新辅助化学放疗后获得pCR与局部晚期直肠癌的癌症结局大大改善有关。未来的研究应评估该人群中pCR率增加与癌症结局改善之间的关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号